Trial Profile

A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lucerastat (Primary)
Indications Fabry's disease; Neuropathic pain
Focus Registrational; Therapeutic Use
Acronyms MODIFY
Sponsors Idorsia Pharmaceuticals

Most Recent Events

11 Oct 2021 Results presented in the Idorsia Pharmaceuticals Media Release.
11 Oct 2021 Primary endpoint has not been met. (Change from baseline to Month 6 in the modified Brief Pain Inventory-Short Form 3 (BPI-SF3) score of neuropathic pain at its worst in the last 24 hours), according to an Idorsia Pharmaceuticals media release.
16 Sep 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com